v3.26.1
Segment Reporting - Summary of Segment Reporting Information (Detail)
¥ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2025
CNY (¥)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
CNY (¥)
Dec. 31, 2023
CNY (¥)
Revenues:        
Revenues from services ¥ 316,111 $ 45,203 ¥ 290,738 ¥ 345,030
Revenues from sales of products 223,457 31,954 225,084 192,405
Total revenues 539,568 77,157 515,822 537,435
Cost of revenues: (136,654) (19,542) (153,422) (174,208)
Gross profit 402,914 57,615 362,400 363,227
Central laboratory business [Member]        
Revenues:        
Revenues from services 159,993 22,878 175,649 232,812
Revenues from sales of products 0 0 0 0
Total revenues 159,993 22,878 175,649 232,812
Cost of revenues: (22,417) (3,205) (33,808) (49,473)
Gross profit 137,576 19,673 141,841 183,339
In-hospital business [Member]        
Revenues:        
Revenues from services 578 83 (592) (3,704)
Revenues from sales of products 223,457 31,954 225,084 192,405
Total revenues 224,035 32,037 224,492 188,701
Cost of revenues: (57,337) (8,200) (65,099) (72,570)
Gross profit 166,698 23,837 159,393 116,131
Pharma research and development services [Member]        
Revenues:        
Revenues from services 155,540 22,242 115,681 115,922
Revenues from sales of products 0 0 0 0
Total revenues 155,540 22,242 115,681 115,922
Cost of revenues: (56,900) (8,137) (54,515) (52,165)
Gross profit ¥ 98,640 $ 14,105 ¥ 61,166 ¥ 63,757